ABSTRACT
Purpose@#To compare the thickness of the processed pericardial patch graft for glaucoma implant tube coverage using anterior segment optical coherence tomography (AS-OCT). @*Methods@#Thicknesses of seven samples of two pericardial patch grafts (Tutoplast pericardium, IOP Inc, Costa Mesa, CA, USA; pericardium LYO, DCI Donor Services, Inc., Nashville, TN, USA) were measured using AS-OCT (CASIA2, Tomey Corporation, Nagoya, Japan). The thickness of each sample was measured at the center and eight points with 45-degree angular distance, 2 mm from the center. The thickness was measured using AS-OCT program tools. @*Results@#The median thicknesses were 219 μm for Tutoplast pericardium and 157 μm for pericardium LYO. Tutoplast pericardium was significantly thicker than pericardium LYO (p = 0.001); pericardium LYO had a wider interquartile range within each sample, compared to Tutoplast pericardium (p = 0.017). @*Conclusions@#The thickness of the Tutoplast pericardium was greater and less variable than that of the pericardium LYO. These findings should be considered when choosing processed pericardium for coverage of glaucoma implants.
ABSTRACT
Purpose@#We evaluated the efficacy and safety of micropulse transscleral cyclophotocoagulation (MP-TSCPC) in refractoryglaucoma patients. @*Methods@#A retrospective chart review was performed for 23 eyes of 23 patients with refractory glaucoma who were followed for6 months after MP-TSCPC. @*Results@#The mean preoperative intraocular pressure (IOP) was 39.3 ± 15.8 mmHg and the mean number of antiglaucoma medicationswas 2.6 ± 0.6. Both significantly decreased at 6 months to 23.8 ± 15.4 mmHg (p = 0.002) and 1.8 ± 1.1 (p = 0.018).Surgical success was defined as a postoperative IOP decrease from 6-21 mmHg or more than 20% reduction from baseline. Thesuccess rate was 65.2% at 6 months. Complications of MP-TSCPC included subconjunctival hemorrhage in 6 eyes (26.1%), ocularpain in 16 eyes (69.6%), anterior chamber inflammation in 17 eyes (73.9%), and hypotony in 2 eyes (8.7%). @*Conclusions@#MP-TSCPC in patients with refractory glaucoma showed a reduction in IOP and the number of antiglaucoma medicationsin the short-term. However, additional studies are needed to determine the optimal laser settings for maximum efficacyand safety.
ABSTRACT
PURPOSE: To evaluate the effect and safety of subconjunctival bevacizumab injection immediately after primary pterygium surgery. METHODS: From October 2010 to June 2011, 54 patients (54 eyes) with primary pterygium who had received pterygium excision with the bare sclera technique were evaluated. Twenty-seven patients (27 eyes) in the bevacizumab group received a subconjunctival injection of 5 mg (0.2 ml) bevacizumab and 27 patients (27 eyes) in the control group received a subconjunctival injection of 0.2 ml balanced salt solution immediately after surgery. At the 6-month follow-up, the degree of fibrovascular tissue proliferation, the recurrence rate of pterygium and the effect of wound healing were analyzed prospectively. RESULTS: One month after the surgery, the degree of fibrovascular tissue proliferation was inhibited in the bevacizumab group compared to the control group (p = 0.028). However, 3 to 6 months after surgery, there was no significant difference between the 2 groups. In addition, there was no significant difference between the 2 groups in the recurrence rate of pterygium and wound healing after surgery. CONCLUSIONS: Subconjunctival bevacizumab injection after primary pterygium surgery inhibited the degree of fibrovascular tissue proliferation for 1 month and safe for wound healing. Subconjunctival bevacizumab injection has the potential for adjunctive therapy after pterygium surgery.
Subject(s)
Humans , Follow-Up Studies , Prospective Studies , Pterygium , Recurrence , Sclera , Wound Healing , BevacizumabABSTRACT
PURPOSE: To evaluate the effects of conjunctivochalasis surgery using a high-frequency radio-wave electrosurgical unit. METHODS: Twenty-seven eyes of 14 patients with conjuctivochalasis who received surgeries with shrinkage of the inferior bulbar conjunctiva using a high-frequency radio-wave electrosurgical unit (Ellman surgitron(R)) were evaluated. Conjuctivochalasis grade, the ocular symptoms, Ocular Surface Disease Index (OSDI), tear film break-up time (BUT), Schirmer test, and corneal staining with fluorescein were measured preoperatively, at 3 months postoperatively, and analyzed prospectively. RESULTS: Three months after the surgery, all patients' conjunctivochalasis became grade 0, and the ocular symptoms, OSDI score, BUT, and corneal staining with fluorerscein were also improved. Additionally, there were no specific complications during the follow-up period. CONCLUSIONS: Conjunctivochalasis surgery using a high-frequency radio-wave electrosurgical unit produced an effective improvement in conjuctivochalasis grade and symptoms and appeared to be a simple and safe procedure.